Zacks Investment Research·1d ago
CME Group Expands Equity Derivatives With New Factor FuturesCME expands equity derivatives with new factor futures, offering targeted exposure, margin offsets and flexible trading for institutions.
CME Group's 2026Q2 revenue surged to $1.7B with a 199.1% NII growth, driven by record trading volumes and exceptional operating leverage, as the efficiency ratio improved to 4.4%. However, a 216% spike in provision expenses to $568.3M and an EPS miss of $0.06 ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue reached $1.7B in 2026Q2, up 199.1% in NII growth, with the efficiency ratio improving to 4.4% from 20.2% a year earlier, though EPS of $2.88 missed consensus by $0.06.
CME Group operates the world’s leading derivatives marketplace, providing critical infrastructure for futures and options across interest rates, equities, currencies, commodities, and cryptocurrencies. Its network effects mean that liquidity attracts more traders, which in turn strengthens its dominant position.
CME posted a 6.32% revenue increase in 2025, reaching $6.51 billion. The growth is driven by strong trading volumes, especially in the Market Data segment, and has resulted in record operating income and Adjusted EPS.
Geopolitical uncertainty, interest‑rate swings, and economic shifts increase market volatility, which directly benefits CME by boosting trading activity and the demand for hedging instruments.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 22, 2026 | $2.99+2.7% vs $2.91 | $1.7B+1.4% vs $1.7B |
Q2 2026 Apr 22, 2026 | $3.36+0.6% vs $3.34 | $1.9B+0.3% vs $1.9B |
Q1 2026 Feb 4, 2026 | $2.77+0.7% vs $2.75 | $1.6B+0.1% vs $1.6B |
Q4 2025 Oct 22, 2025 | $2.68+1.9% vs $2.63 | $1.5B+0.5% vs $1.5B |
CME expands equity derivatives with new factor futures, offering targeted exposure, margin offsets and flexible trading for institutions.
What a difference a year makes. In fall 2025, markets expected 2026 to bring rate cuts.
The Fed hiked to 4%, Generac jumped 40% on Amazon warrants, and more
This final deep dive unpacks Nasdaq's strategic evolution beyond its traditional exchange roots into a powerhouse driven by high-margin software, sticky financial crime tech, and recurring solutions. We analyze the upcoming December 6 launch of 23-hour trading, evaluating how expanded operating hours unlock greater utilization across Nasdaq's capital access platforms and software subscriptions. The article ends with a five-point scorecard comparing Nasdaq, ICE, CME, and Cboe, detailing the two winners of this project.
Benchmark CME against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CME Group Inc. (CME)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $267.21 | $96.08B | 23.94 | 7.06% | 62.02% | 14.65% | 4.09% | |
| $152.93 | $86.25B | 26.50 | 9.27% | 30% | 13.78% | — | |
| $266.83 | $27.92B | 25.61 | 15.31% | 26.73% | 25.75% | — | |
| $94.50 | $52.82B | 30.58 | 9.86% | 22.6% | 16.3% | — | |
| $163.43 | $5.75B | 24.54 | 3.85% | 35.23% | 24.48% | — | |
| $548.88 | $39.9B | 35.28 | 9.51% | 40.74% | — | — |
CME Group Inc. (CME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CME Group Inc. (CME) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 22, 2026·SEC
Jun 17, 2026·SEC
Get notified when CME posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CME Group Inc. (CME) stock FAQ — growth, dividends, profitability & financials explained
CME Group Inc. (CME) grew revenue by 7.1% over the past year. This is steady growth.
Yes, CME Group Inc. (CME) is profitable, generating $4.27B in net income for fiscal year 2025 (62.0% net margin).
Yes, CME Group Inc. (CME) pays a dividend with a yield of 4.09%. This makes it attractive for income-focused investors.
CME Group Inc. (CME) has a return on equity (ROE) of 14.6%. This is reasonable for most industries.
CME Group Inc. (CME) has a net interest margin (NIM) of -0.1%. NIM has been under pressure due to interest rate environment.
CME Group Inc. (CME) has an efficiency ratio of 21.2%. This is excellent, indicating strong cost control.
